Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability.

It is challenging to deliver molecules to the brain for diagnosis and treatment of brain diseases. This is primarily because of the presence of the blood-brain barrier (BBB), which restricts the entry of many molecules into the brain. In this study, cyclic-ADT peptides (ADTC1, ADTC5, and ADTC6) have been shown to modify the BBB to enhance the delivery of marker molecules [e.g., (14) C-mannitol, gadolinium-diethylenetriaminepentacetate (Gd-DTPA)] to the brain via the paracellular pathways of the BBB. The hypothesis is that these peptides modulate cadherin interactions in the adherens junctions of the vascular endothelial cells forming the BBB to increase paracellular drug permeation. In vitro studies indicated that ADTC5 had the best profile to inhibit adherens junction resealing in Madin-Darby canine kidney cell monolayers in a concentration-dependent manner (IC50 = 0.3 mM) with a maximal response at 0.4 mM. Under the current experimental conditions, ADTC5 improved the delivery of (14) C-mannitol to the brain about twofold compared with the negative control in the in situ rat brain perfusion model. Furthermore, ADTC5 peptide increased in vivo delivery of Gd-DTPA to the brain of Balb/c mice when administered intravenously. In conclusion, ADTC5 has the potential to improve delivery of diagnostic and therapeutic agents to the brain.

[1]  B. Engelhardt,et al.  Novel insights into the development and maintenance of the blood–brain barrier , 2014, Cell and Tissue Research.

[2]  Donald W. Miller,et al.  Modulation of Blood–Brain Barrier Permeability in Mice Using Synthetic E-Cadherin Peptide , 2014, Molecular pharmaceutics.

[3]  J. Leppänen,et al.  Design, Synthesis and Brain Uptake of LAT1-Targeted Amino Acid Prodrugs of Dopamine , 2013, Pharmaceutical Research.

[4]  T. Davis,et al.  Physiology and Pathophysiology of the Blood-brain Barrier: P-glycoprotein and Occludin Trafficking as Therapeutic Targets to Optimize Central Nervous System Drug Delivery Dynamic Nature of the Blood-brain Barrier Protein Trafficking as a Therapeutic Target to Modulate Bbb Function Altered P-glycopro , 2022 .

[5]  Lihong Liu,et al.  Modern methods for delivery of drugs across the blood-brain barrier. , 2012, Advanced drug delivery reviews.

[6]  C. Hrycyna,et al.  Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. , 2012, Journal of the American Chemical Society.

[7]  H. Glaeser,et al.  Interaction of innovative small molecule drugs used for cancer therapy with drug transporters , 2012, British journal of pharmacology.

[8]  K. Aboody,et al.  Strategies for enhancing antibody delivery to the brain. , 2011, Biochimica et biophysica acta.

[9]  R. Rao,et al.  CaV1.3 Channels and Intracellular Calcium Mediate Osmotic Stress-induced N-terminal c-Jun Kinase Activation and Disruption of Tight Junctions in Caco-2 Cell Monolayers* , 2011, The Journal of Biological Chemistry.

[10]  B. Honig,et al.  Structure and binding mechanism of vascular endothelial cadherin: a divergent classical cadherin. , 2011, Journal of molecular biology.

[11]  A. Calcagno,et al.  Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides. , 2011, Molecular pharmaceutics.

[12]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[13]  Chen Jiang,et al.  Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. , 2009, Biomaterials.

[14]  R. Rao.  Occludin Phosphorylation in Regulation of Epithelial Tight Junctions , 2009, Annals of the New York Academy of Sciences.

[15]  M. Deli,et al.  Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. , 2009, Biochimica et biophysica acta.

[16]  J. Nutt,et al.  Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.

[17]  Pasi Soininen,et al.  Activity and stability of human kallikrein‐2‐specific linear and cyclic peptide inhibitors , 2007, Journal of peptide science : an official publication of the European Peptide Society.

[18]  B. Volk,et al.  Expression and function of cytochrome p450 in brain drug metabolism. , 2007, Current drug metabolism.

[19]  T. Siahaan,et al.  Structure and function of the intercellular junctions: barrier of paracellular drug delivery. , 2006, Current pharmaceutical design.

[20]  Hong Zhao,et al.  Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. , 2006, Bioconjugate chemistry.

[21]  T. Bártfai,et al.  VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. , 2001, Experimental cell research.

[22]  K. Audus,et al.  Improving the Selectivity of HAV-Peptides in Modulating E-Cadherin-E-Cadherin Interactions in the Intercellular Junction of MDCK Cell Monolayers , 2001, Pharmaceutical Research.

[23]  O. Blaschuk,et al.  A Novel Family of Cyclic Peptide Antagonists Suggests That N-cadherin Specificity Is Determined by Amino Acids That Flank the HAV Motif* , 2000, The Journal of Biological Chemistry.

[24]  R. Bartus,et al.  Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. , 1999, Neuro-oncology.

[25]  T. Williams,et al.  Solution stability of linear vs. cyclic RGD peptides. , 1999, The journal of peptide research : official journal of the American Peptide Society.

[26]  E. Dejana,et al.  Differential Localization of VE- and N-Cadherins in Human Endothelial Cells: VE-Cadherin Competes with N-Cadherin for Junctional Localization , 1998, The Journal of cell biology.

[27]  W. Mark Saltzman,et al.  Localized Delivery of Proteins in the Brain: Can Transport Be Customized? , 1998, Pharmaceutical Research.

[28]  K. Audus,et al.  Modulation of cellular adhesion in bovine brain microvessel endothelial cells by a decapeptide , 1997, Brain Research.

[29]  C. Williams,et al.  Peptidases, Peptides, and the Mammalian Blood–Brain Barrier , 1993, Journal of neurochemistry.

[30]  W. Cosolo,et al.  Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. , 1989, The American journal of physiology.

[31]  S. Rapoport,et al.  An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.

[32]  E P Frenkel,et al.  Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. , 1984, Neurosurgery.

[33]  D. Groothuis,et al.  Brain tumors and the blood—brain barrier , 1982, Trends in Neurosciences.

[34]  K R Maravilla,et al.  Osmotic blood-brain barrier disruption: Computerized tomographic monitoring of chemotherapeutic agent delivery , 1979 .

[35]  J. Laurence,et al.  N Backbone Assignment of the EC1 Domain of Human E-Cadherin , 2015 .

[36]  C. V. Van Itallie,et al.  Measuring size-dependent permeability of the tight junction using PEG profiling. , 2011, Methods in molecular biology.

[37]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[38]  R. Shivers,et al.  Capillary junctions of the rat are not affected by osmotic opening of the blood-brain barrier , 2004, Acta Neuropathologica.

[39]  K. Audus,et al.  Increasing Paracellular Porosity by E-Cadherin Peptides: Discovery of Bulge and Groove Regions in the EC1-Domain of E-Cadherin , 2004, Pharmaceutical Research.